These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

628 related items for PubMed ID: 12915670

  • 1. Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys.
    Wickman S, Kajantie E, Dunkel L.
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3785-93. PubMed ID: 12915670
    [Abstract] [Full Text] [Related]

  • 2. Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature.
    Hero M, Mäkitie O, Kröger H, Nousiainen E, Toiviainen-Salo S, Dunkel L.
    Horm Res; 2009 Aug; 71(5):290-7. PubMed ID: 19339794
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of P450 aromatase enhances gonadotropin secretion in early and midpubertal boys: evidence for a pituitary site of action of endogenous E.
    Wickman S, Dunkel L.
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4887-94. PubMed ID: 11600558
    [Abstract] [Full Text] [Related]

  • 4. Novel treatment of short stature with aromatase inhibitors.
    Dunkel L, Wickman S.
    J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):345-56. PubMed ID: 14623531
    [Abstract] [Full Text] [Related]

  • 5. The role of sex steroids in the regulation of insulin sensitivity and serum lipid concentrations during male puberty: a prospective study with a P450-aromatase inhibitor.
    Wickman S, Saukkonen T, Dunkel L.
    Eur J Endocrinol; 2002 Mar; 146(3):339-46. PubMed ID: 11888840
    [Abstract] [Full Text] [Related]

  • 6. Estrogen suppression in males: metabolic effects.
    Mauras N, O'Brien KO, Klein KO, Hayes V.
    J Clin Endocrinol Metab; 2000 Jul; 85(7):2370-7. PubMed ID: 10902781
    [Abstract] [Full Text] [Related]

  • 7. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial.
    Hero M, Norjavaara E, Dunkel L.
    J Clin Endocrinol Metab; 2005 Dec 01; 90(12):6396-402. PubMed ID: 16189252
    [Abstract] [Full Text] [Related]

  • 9. The effect of aromatase inhibition on sex steroids, gonadotropins, and markers of bone turnover in older men.
    Taxel P, Kennedy DG, Fall PM, Willard AK, Clive JM, Raisz LG.
    J Clin Endocrinol Metab; 2001 Jun 01; 86(6):2869-74. PubMed ID: 11397902
    [Abstract] [Full Text] [Related]

  • 10. Treatment of delayed male puberty: efficacy of aromatase inhibition.
    Dunkel L, Wickman S.
    J Pediatr Endocrinol Metab; 2001 Jun 01; 14 Suppl 6():1541-6. PubMed ID: 11837512
    [Abstract] [Full Text] [Related]

  • 11. Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men.
    Leder BZ, Finkelstein JS.
    Osteoporos Int; 2005 Dec 01; 16(12):1487-94. PubMed ID: 15856361
    [Abstract] [Full Text] [Related]

  • 12. Differential effects of androgens and estrogens on bone turnover in normal men.
    Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS.
    J Clin Endocrinol Metab; 2003 Jan 01; 88(1):204-10. PubMed ID: 12519853
    [Abstract] [Full Text] [Related]

  • 13. Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats.
    Vanderschueren D, van Herck E, Nijs J, Ederveen AG, De Coster R, Bouillon R.
    Endocrinology; 1997 Jun 01; 138(6):2301-7. PubMed ID: 9165015
    [Abstract] [Full Text] [Related]

  • 14. Pubertal upregulation of erythropoiesis in boys is determined primarily by androgen.
    Hero M, Wickman S, Hanhijärvi R, Siimes MA, Dunkel L.
    J Pediatr; 2005 Feb 01; 146(2):245-52. PubMed ID: 15689918
    [Abstract] [Full Text] [Related]

  • 15. Effects of aromatase inhibitors letrozole and anastrazole on bone metabolism and steroid hormone levels in intact female rats.
    Kumru S, Yildiz AA, Yilmaz B, Sandal S, Gurates B.
    Gynecol Endocrinol; 2007 Oct 01; 23(10):556-61. PubMed ID: 17952760
    [Abstract] [Full Text] [Related]

  • 16. Bone mineral density in girls and boys at different pubertal stages: relation with gonadal steroids, bone formation markers, and growth parameters.
    Yilmaz D, Ersoy B, Bilgin E, Gümüşer G, Onur E, Pinar ED.
    J Bone Miner Metab; 2005 Oct 01; 23(6):476-82. PubMed ID: 16261455
    [Abstract] [Full Text] [Related]

  • 17. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F, Frisch H, Geyer G, Hörl WH, Mayer G, Luger A.
    J Nephrol; 2004 Oct 01; 17(1):87-94. PubMed ID: 15151263
    [Abstract] [Full Text] [Related]

  • 18. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 01; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 19. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty.
    Boot AM, De Muinck Keizer-Schrama S, Pols HA, Krenning EP, Drop SL.
    J Clin Endocrinol Metab; 1998 Feb 01; 83(2):370-3. PubMed ID: 9467543
    [Abstract] [Full Text] [Related]

  • 20. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
    Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.
    Breast Cancer Res Treat; 2015 Nov 01; 154(2):263-73. PubMed ID: 26536870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.